A 19-year-old male student presents with a 4-month history of progressive left-sided nasal obstruction and recurrent nosebleeds that have required hospital visits for epistaxis control. He denies systemic symptoms, weight loss, or constitutional complaints. Nasal endoscopy reveals a smooth, pulsatile, reddish mass in the left nasopharynx. MRI shows a heterogeneous mass with multiple flow voids and widening of the left pterygopalatine fossa. The mass extends into the sphenoid sinus. Before surgical planning, which of the following is the most appropriate next step in management?

Explanation

## Preoperative Management of Nasopharyngeal Angiofibroma ### Clinical Context **Key Point:** This patient has a classic presentation of nasopharyngeal angiofibroma (NAF) with imaging confirmation. The next critical step is **preoperative angiographic embolization** to reduce intraoperative blood loss and improve surgical safety. ### Why Embolization Before Surgery? ### Rationale for Embolization | Aspect | Rationale | |--------|----------| | **Vascularity** | NAF is highly vascular, fed primarily by the sphenopalatine artery (branch of maxillary artery) | | **Hemorrhage risk** | Intraoperative bleeding can be life-threatening; embolization reduces blood supply by 60–80% | | **Surgical access** | Reduced bleeding improves visualization and allows safer endoscopic resection | | **Transfusion avoidance** | Embolization decreases need for massive transfusion | | **Recurrence** | Proper embolization of all feeding vessels reduces recurrence risk | ### Preoperative Angiography & Embolization Protocol 1. **Selective angiography** of bilateral maxillary arteries and ascending pharyngeal artery to identify all feeding vessels 2. **Embolization** using particles (polyvinyl alcohol, gelatin sponge) or coils 24–48 hours before surgery 3. **Post-embolization imaging** to confirm vessel occlusion and assess residual blood supply 4. **Endoscopic resection** performed within 24–48 hours of embolization (before collateral circulation develops) ### Management Algorithm for NAF ```mermaid flowchart TD A[Suspected NAF on clinical + imaging grounds]:::outcome --> B[Confirm diagnosis with MRI/CT]:::action B --> C{Extent of disease?}:::decision C -->|Small, limited| D[Consider direct endoscopic resection]:::action C -->|Large, extensive, highly vascular| E[Preoperative angiography]:::action E --> F[Selective embolization of feeding vessels]:::action F --> G[Wait 24-48 hours for stabilization]:::action G --> H[Endoscopic resection under GA]:::action H --> I[Histopathology confirms benign angiofibroma]:::outcome I --> J{Residual disease on postop imaging?}:::decision J -->|No| K[Follow-up at 6-12 months]:::action J -->|Yes| L[Consider repeat embolization + resection]:::action ``` ### Why Other Options Are Incorrect **High-Yield:** **Never perform biopsy of a suspected NAF** — the risk of severe hemorrhage is unacceptable. Diagnosis is made on imaging (CT/MRI) and confirmed on histology after resection. **Clinical Pearl:** Immediate resection without embolization in a highly vascular NAF can result in intraoperative hemorrhage requiring emergency transfusion, airway compromise, or conversion to open approach. Embolization is the standard of care in most centers. ### Hormonal Therapy **Key Point:** Testosterone antagonists (e.g., flutamide, bicalutamide) have been studied as adjuvant therapy for recurrent or unresectable NAF, but they are **not primary treatment** and have variable efficacy. Surgery (with embolization) remains the definitive treatment. ### Outcomes & Follow-up - **Recurrence rate:** 10–30% after endoscopic resection (higher if incompletely resected) - **Imaging follow-up:** MRI at 6–12 months postoperatively - **Late recurrence:** Can occur years later; long-term surveillance recommended - **Malignant transformation:** Extremely rare; NAF remains benign even if recurrent